Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

483
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
483
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

821
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
821
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

970
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
970
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

761
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
761
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

306
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
306

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.

Blood advances·2026
Same author

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

Nature immunology·2026
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Blood·2026
Same author

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances·2026

Related Experiment Video

Updated: Mar 23, 2026

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

784

Richter syndrome: pathogenesis and management.

Davide Rossi1, Gianluca Gaidano1

  • 1Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.

Seminars in Oncology
|April 5, 2016
PubMed
Summary

Richter syndrome (RS), an aggressive lymphoma in chronic lymphocytic leukemia (CLL) patients, has identifiable risk biomarkers. Early detection and treatment, including chemotherapy and stem cell transplant, improve outcomes for this rare but serious condition.

Keywords:
Chronic lymphocytic leukemiaDiffuse large B-cell lymphomaNOTCH1Richter syndromeSubset 8

More Related Videos

Organotypic Retinal Explant Cultures from Macaque Monkey
10:32

Organotypic Retinal Explant Cultures from Macaque Monkey

Published on: August 24, 2022

1.7K

Related Experiment Videos

Last Updated: Mar 23, 2026

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

784
Organotypic Retinal Explant Cultures from Macaque Monkey
10:32

Organotypic Retinal Explant Cultures from Macaque Monkey

Published on: August 24, 2022

1.7K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Richter syndrome (RS) is a rare but aggressive transformation of chronic lymphocytic leukemia (CLL).
  • Identifying patients at risk for RS is crucial for timely intervention.
  • Understanding the molecular underpinnings of RS is key to improving patient outcomes.

Purpose of the Study:

  • To review biomarkers for identifying chronic lymphocytic leukemia (CLL) patients at risk of Richter syndrome (RS).
  • To discuss diagnostic tools, including (18)FDG-PET/CT, for suspected RS.
  • To summarize the molecular landscape and prognostic factors in RS.

Main Methods:

  • Literature review of biomarkers, diagnostic modalities, and molecular lesions associated with Richter syndrome.
  • Analysis of prognostic factors, including clonal relationship between CLL and lymphoma.

Main Results:

  • NOTCH1 mutations and specific B-cell receptor configurations are potential biomarkers for RS risk in CLL.
  • Molecular lesions in TP53, CDKN2A, NOTCH1, and MYC are implicated in ~90% of RS cases, contributing to chemoresistance and rapid kinetics.
  • The clonal relationship between CLL and the lymphoma clone is a critical prognostic factor.

Conclusions:

  • Early identification of at-risk CLL patients using biomarkers and advanced imaging like (18)FDG-PET/CT can aid diagnosis.
  • Targeted therapies addressing key molecular lesions may offer new treatment avenues.
  • Rituximab-based chemotherapy followed by stem cell transplant for eligible patients forms the current standard of care for RS.